Eustace, A., Mani, N., Span, P., Irlam, J., Taylor, J., Betts, G., . . . West, C. (2013). A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Chicago Style (17th ed.) CitationEustace, A., et al. A 26-gene Hypoxia Signature Predicts Benefit from Hypoxia-modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. 2013.
MLA (9th ed.) CitationEustace, A., et al. A 26-gene Hypoxia Signature Predicts Benefit from Hypoxia-modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. 2013.
Warning: These citations may not always be 100% accurate.